Pharming Group Delays Leniolisib EU Approval
Company Announcements

Pharming Group Delays Leniolisib EU Approval

Pharming Group (PHAR) has released an update.

Pharming Group N.V. has provided an update on the European regulatory review of leniolisib, indicating that while the CHMP has acknowledged the drug’s positive clinical benefit and safety, there is a delay in approval due to a manufacturing request. The company, which maintains its 2022 revenue guidance, has already begun addressing the CHMP’s requirements and seeks approval for leniolisib, currently available in the U.S., for patients with APDS in Europe.

For further insights into PHAR stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyPharming price target lowered to EUR 1.60 from EUR 1.65 at RBC Capital
TheFlyPharming price target lowered to $30 from $31 at Oppenheimer
Brian AndersonIs PHAR a Buy, Before Earnings?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App